TIDMMHC
RNS Number : 0385V
MyHealthChecked PLC
03 April 2023
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED
UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014
WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL)
ACT 2018, AS AMED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A
REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO
BE IN THE PUBLIC DOMAIN.
MyHealthChecked PLC
("MyHealthChecked" or the "Company")
Preliminary Results
Year Ended 31 December 2022
MyHealthChecked PLC (AIM: MHC), the consumer home-testing
healthcare company, announces its preliminary results for the year
ended 31 December 2022, a successful year with strong revenue
growth and profitability achieved for the second consecutive year,
driven by significant demand from the top high street pharmacy
retailers for COVID Lateral Flow Tests ("LFTs").
MyHealthChecked remains focused on delivering high-quality
wellness testing solutions and guidance to meet the evolving needs
of our customers and help them navigate this new and exciting
space.
Financial highlights
-- Revenue up 36% to GBP22.3m (2021: GBP16.4m)
-- Gross Profit of GBP4.6m (2021: GBP5.1m)
-- Adjusted EBITDA of GBP2.3m (2021: GBP2.7m) - reflecting the change
in product mix away from higher margin PCR testing to the distribution
of LFTs
-- Net cash generated from operating activities of GBP1.6m (2021:
GBP3.0m)
-- Cash balance at year end of GBP7.6m (2021: GBP6.4m) - whilst continuing
to invest across the business for future growth
-- Strong cash position to ensure next growth phases remain self-funded
Commercial and operational highlights
-- Actively developing B2B2C customer relationships in preparation
to launch an expanded portfolio of at-home wellness tests nationwide
in 2023
-- Soft launch of initial DNA at-home wellness portfolio in July
2022
-- Reinvestment of earnings into developing new products for pipeline
of at-home wellness tests and building scalable, digital healthcare-centric
technology
-- Capabilities strengthened by establishing key relationships
with high-quality laboratory and kit-build partners
-- Working towards ISO 27001 and migration of digital Quality Management
System ('QMS') to support key compliance activity including
transition to the requirements of the In Vitro Diagnostics Regulation
("IVDR").
The full Group Annual Report and Financial Statements will be
posted to shareholders today, together wth the notice of the AGM,
and will also be available shortly at
www.investors.myhealthcheckedplc.com .
Penny McCormick, Chief Executive Officer of MyHealthChecked PLC,
said : " MHC has not only established itself as a player in the
wellness industry but has also achieved excellent financial results
in the last two years. Our commitment to innovation, customer
satisfaction, and financial stability and management has set us on
a path to delivering our goal of sustained liquidity. As we enter
an investment phase, we are confident in our ability to execute our
plans and scale our operations to meet the demand of our growing
customer base. With a robust balance sheet and a team of highly
skilled professionals, we are well-positioned to deliver a solid
business in 2023 and beyond. The upcoming launch of new tests and
further development of our digital platform presents a strong
opportunity to create value for our shareholders and solidify our
position as a leading wellness company."
Investor Presentation
Penny McCormick, Chief Executive Officer and Nicholas Edwards,
Chief Financial Officer, will provide a live presentation relating
to the preliminary results via the Investor Meet Company platform
today (Monday 3 April 2023) at 4:30pm BST. The presentation is open
to all existing and potential shareholders.
Investors can sign up to Investor Meet Company for free and
register for the presentation via the link below:
https://www.investormeetcompany.com/myhealthchecked-plc/register-investor
MyHealthChecked PLC www.myhealthcheckedplc.com
P enny McCormick , Chief Executive via Walbrook PR
Officer
Nicholas Edwards, Chief Financial
Officer
SPARK Advisory Partners Limited Tel: +44 (0)20 3368 3550
(NOMAD)
Neil Baldwin
Dowgate Capital Limited (Broker) Tel: +44 (0)20 3903 7715
David Poutney / Nicholas Chambers
Walbrook PR Ltd (Media Tel: +44 (0)20 7933 8780 or myhealthcheckedplc@walbrookpr.com
& IR)
Paul McManus / Alice Woodings Mob: +44 (0)7980 541 893 / +44 (0)7407
804 654
About MyHealthChecked PLC ( www.myhealthcheckedplc.com )
MyHealthChecked PLC, based in Cardiff, is an AIM-quoted
pioneering UK healthcare company focused on a range of at-home
healthcare and wellness tests.
MyHealthChecked is the umbrella brand of a range of at-home
rapid tests, as well as DNA, RNA and blood sample collection kits
which have been created to support customers on their journeys to
wellness. The tests are lateral-flow self-tests, and the sample
collection kits enable the collection of blood, urine, nasal or
mouth swab samples that are analysed in partner laboratories for a
range of biomarkers. The tests will also be made available online
and will be viable for over-the-counter purchase.
The MyHealthChecked portfolio has been identified as part of a
change in mindset as customers become more familiar with the
concept of accessible healthcare in the growing at home testing kit
market with a focus on accessibility at the right price, led by
UK-based experts.
JOINT CHAIRMAN AND CHIEF EXECUTIVE'S REPORT
MyHealthChecked has had a successful year in 2022, with strong
revenue growth and profitability achieved for the second
consecutive year. We surpassed management expectations with our
financial performance, maintaining a reliable track record of
delivery for our valued retail customers and partners.
Despite the unpredictable demand for our services throughout the
challenging COVID period, we were able to deliver and meet the high
demands of our customers in terms of volume. Our revenue increased
by GBP5.9m (36%) to GBP22.3m, and this growth has enabled us to
achieve our ultimate goal of a second year of positive cash flow.
We ended the year with a cash balance of GBP7.6m (2021: GBP6.4m),
providing us with substantial working capital to drive the business
forward in 2023 and beyond.
It's a very exciting time for consumer healthcare and
specifically testing, and in our many years in the consumer
healthcare and testing space, we have never felt so energised
around the potential for consumer self-testing. We are excited
about how this can positively impact the lives of millions as we
embrace preventative methods of care, can make a major difference
to individuals' lives, and ultimately release the pressure on much
strained healthcare services. Never before has there been so much
information and guidance available for us to make informed
decisions on how we reduce our future risks.
As we navigate this dynamic period of behavioural change, MHC
remains focused on delivering high-quality wellness testing
solutions and guidance to meet the evolving needs of our customers
and help them navigate this new and exciting space.
COVID-19 testing
COVID has been a major catalyst for this change in customer
behaviour, and in the past two years we have seen the market
dominated by COVID testing. This familiarisation of both
self-testing and laboratory testing has given customers confidence
and normalised testing outside of a medical setting.
Throughout 2021 and 2022, COVID testing has been a major part of
our business, with over 17 million tests delivered to the market
this past year.
However, as a result in the shift in product mix from higher
margin Polymerase Chain Reaction ("PCR") testing to lateral flow
tests ("LFTs") during the current year, we have seen gross margins
in our COVID portfolio reducing. However, post period we are
launching a new testing portfolio to counter this trend, whilst we
continue to deliver value to our customers.
Retail launches
We are actively developing B2B2C customer relationships and are
preparing to launch an expanded portfolio of at-home wellness tests
nationwide. Since the soft-launch of our initial DNA portfolio in
July of last year we have remained focused on developing our
wellness portfolio and supporting our retail customers in expanding
their own commercial strategies to meet their customers' needs for
at-home testing.
Market reports indicate significant growth potential for the
home testing market, with projections indicating the market will
reach $45.58 billion by 2031 (source : Allied Market Research Nov
2022, At-Home Testing Market Research 2031, Author(s) : Vikita T,
Shubham S , Onkar S).
In order to play a major role in this market, we have
prioritised building strong relationships with our retail partners,
with the goal of reaching as many end users as possible. Beyond our
retail partner launches we plan to expand our core target base,
while keeping a close eye on market trends to ensure an optimal
user journey, and positioning ourselves as cost-effective and
understanding of the current economic climate.
Product portfolio
Amid the challenges of the COVID era, we positioned ourselves as
a leading provider of products and services to meet the demand for
testing - and we succeeded. Our unique multi-platform portfolio of
tests offers users access to a variety of test types, sample
collection options, and levels of analysis, enabling us to meet
diverse customer needs. Whether a customer requires an initial
screener, a lab analysis, or a DNA assessment, our tests provide
reliable results and guidance that empower our customers to make
positive changes to their nutrition and lifestyle.
But we don't stop there in our mission to improve our customers'
health in the longer term. Our tests are not just end-products, but
tools that open up a dialogue with the customer and facilitate the
building of a long-term relationship based on guidance, support,
and monitoring. We don't simply provide test results; through our
evolving digital platform we are providing a supportive
relationship and guidance to ensure our customers achieve their
wellness goals.
As a result of our careful cash control, we have entered another
new financial year in a position of strength. We are reinvesting
our earnings into developing new products for our pipeline of
at-home wellness tests and building scalable, digital
healthcare-centric technology. We remain committed to delivering
innovative solutions that meet the evolving needs of our customers
and the broader healthcare industry.
Developing talent within our team
Our new and dynamic management team has been the driving force
in our past and future success. The team's determined "can-do"
mindset, coupled with a customer-first approach and an agile
streamlined delivery methodology is our greatest asset.
In 2022, we restructured our product development process and
grew our team to ensure efficient delivery of milestone sprints. We
also implemented a constant feedback loop, where our customers and
triallists provided input into each iteration of our products
before launch.
As we move forward, we are further strengthening the MHC team
with new resources in product and digital development operations,
and commercial. We have recently appointed a talented individual in
the newly created role of Operations Director and our primary focus
in 2023 is to grow our commercial team to further expand our B2B2C
customer base and drive greater success.
Operations
Despite making the decision to close down our own laboratory
operations due to the downturn in COVID PCR testing in H1 of 2022,
our lean distribution channel has continued to underpin our success
this past year. Our rapid responses to changing customer and market
needs has seen us bring our distribution centre in-house near to
our Cardiff headquarters, and we continue to strengthen our highly
effective operational set-up.
In 2022, we further strengthened our position as a gold-standard
partner by establishing key relationships with high-quality
laboratory and kit-build partners, as well as digital partners.
These proactive and compliant suppliers have further strengthened
our capabilities and added to our credentials.
Compliance
Our regulatory team is fully committed to meet the new
requirements of the In Vitro Diagnostic Regulation ("IVDR") which
affects our products in the UK. We have a robust network of
experienced regulatory partners to support us through the
transitional provisions of the IVDR and we have commenced a
transition to a digital Quality Management System to support us
during this transition.
We have also submitted an application to the Healthcare
Inspectorate Wales ("HIW") which will enable us to offer
doctor-verified testing, and to provide remote phlebotomy services
in the future, whilst safeguarding our customers in line with our
commitments to best practice under HIW.
Investment in future technology
The cash generated from COVID testing has not only allowed us to
define an investment plan around future growth opportunities, it
has also put us in a position of strength where we can achieve our
current plans for the business without the need for additional
working capital. This is a crucial advantage that will allow us to
move forward with confidence. As we worked to expand our testing
portfolio in 2023, we also committed to investing in our digital
platform, the plan for which is to unlock further growth
potential.
Current Trading
While we anticipate a reduction in the demand for COVID tests as
the general public learns how to respond to living with the virus,
we expect that testing will remain an essential part of our
business into 2023 and beyond. We have seen steady sales in 2023,
and as the year progresses, we will establish a new trendline and
will be ready to respond to spikes in demand.
Regarding our new multi-platform range of tests, 2023 will see
us moving beyond our initial soft launch to deliver a national
rollout. W e are confident that the investments that we make in our
portfolio and service will deliver growing revenues in the future
and a digital infrastructure upon which we can build and grow, and
we are energised by the many opportunities ahead.
Summary
MHC has not only established itself as a player in the wellness
industry but has also achieved excellent financial results in the
last two years. Our commitment to innovation, customer
satisfaction, and financial stability and management has set us on
a path to delivering our goal of sustained liquidity. As we enter
an investment phase, we are confident in our ability to execute our
plans and scale our operations to meet the demand of our growing
customer base. With a robust balance sheet and a team of highly
skilled professionals, we are well-positioned to deliver a solid
business in 2023 and beyond. The upcoming launch of new tests and
further development of our digital platform presents a strong
opportunity to create value for our shareholders and solidify our
position as a leading wellness company.
Adam Reynolds Penny McCormick
Chairman Chief Executive Officer
FINANCIAL REVIEW
Income statement
Revenue for the year increased by 36% to GBP22.3m (2021: 16.4m)
due to the significant demand from the top high street pharmacy
retailers for COVID Lateral Flow Tests ("LTFs"). Gross margins
reduced from 31% to 21% reflecting the change in product mix from
the processing of higher margin COVID PCR testing ("PCR") to the
distribution of LFTs in a highly competitive market. In addition,
capitalised costs amounting to GBP328,000 associated with the
development of COVID user interface on the digital platform, were
fully impaired during the current year through cost of sales.
Sales and marketing costs have increased from GBP699,000 to
GBP798,000 due to the increased investment in marketing activities
associated with the new and planned product launches.
Total administrative expenses were broadly comparable to the
prior year at GBP2,343,000 (2021: GBP2,386,000). Excluding the
impairment of intangible assets, share based payments and the
laboratory closure costs other administrative expenses increased to
GBP2,087,000 (2021: GBP1,860,000) largely due to the significant
investment in the development of the digital platform in readiness
for the launch of the new product offerings in 2023. Research and
development costs expensed to administrative expenses in 2022
amounted to GBP546,000 (2021: GBP175,000). As part of our focus on
tight cost control the decision was also taken to close the
Manchester laboratory at a total cost of approximately GBP226,000
as the facility was no longer operating cost effectively following
the drop in demand for PCR "Fit to Fly" tests. The impairment
charge of GBP50,000 in administration expenses relates to patents
and other costs associated with the MYLO/myLotus products
previously capitalised.
The Group's operating profit amounted to GBP1,506,000 (2021:
GBP2,046,000) and, after the release of the provision for
contingent consideration of GBP1m, the impairment of the associated
goodwill of GBP987,000 and net interest payable of GBP2,000 (2021:
GBP2,000) the Group's profit before and after taxation was
GBP1,517,000 (2021: GBP2,004,000) giving a basic earnings per share
of 0.20p (2021: 0.28p) and fully diluted earnings per share of
0.19p (2021: 0.27p).
Adjusted EBITDA is calculated as follows:
2022 2021
GBP'000 GBP'000
----------------------------------------- -------- --------
Operating profit 1,506 2,046
Depreciation and amortisation 222 157
Impairment of intangible assets 378 414
Share based payments (20) 112
Laboratory closure costs (excluding the 171 -
loss on disposal of equipment)
Adjusted EBITDA 2,257 2,729
----------------------------------------- -------- --------
Financial position
The Group's net assets at 31 December 2022 amounted to
GBP8,850,000 (2021: GBP7,113,000). This comprised total assets of
GBP11,428,000 (2021: GBP11,668,000) and total liabilities of
GBP2,578,000 (2021: GBP4,555,000). The total assets included
property, plant and equipment (including right-of-use assets) of
GBP150,000 (2021: GBP163,000) and intangible assets, being
development costs in respect of the digital platform and website,
know-how, goodwill and patent costs, of GBP1,098,000 (2021:
GBP2,289,000). As noted above an impairment provision was made
against the goodwill arising on the acquisition of Nell Health
Limited which was acquired last year.
Cashflow
The Group's cash balance at the year-end was GBP7,608,000 (2021:
GBP6,387,000). The net inflow from operating activities amounted to
GBP1,606,000 (2021: GBP3,014,000), whilst the cash outflows from
investing activities amounted to GBP338,000 (2021: GBP299,000) and
GBP47,000 (2021: GBP3,206,000 inflow) was spent on financing
activities.
Capital management
The Board's objective is to maintain a balance sheet that is
both efficient and delivers long term shareholder value. The Board
continues to monitor the balance sheet to ensure it has an adequate
capital structure.
Key Performance Indicators ("KPIs")
The Board recognises the importance of both financial and
non-financial KPIs in driving appropriate behaviours and enabling
the monitoring of Group performance.
The key financial KPIs monitored by the Board are revenue, gross
margin and EBITDA which are discussed under the review of the
Income Statement above. In addition, the Board also reviews cash
and working capital balances on a monthly basis.
With regard to non-financial KPIs, the Board monitors its
relationship with key customers and suppliers, the motivation and
retention of employees and progress against the planned development
of the digital platform and new product offerings.
Events after the reporting year
On 17 January 2023 the Court approved the reduction of the share
capital of the Company which involved the cancellation of all the
Deferred Shares, the Share Premium Account and the Capital
Redemption Reserve. The purpose of the Capital Reduction was to
create distributable reserves.
Nicholas Edwards
Chief Financial Officer
FINANCIAL STATEMENTS
The notes to the Financial Statement are an integral part of
these financial statements and will be available in full in the
Group Annual Report and Financial Statements which will be
available on the Company website later today.
www.investors.myhealthcheckedplc.com
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
For The Year Ended 31 December 2022
2022 2021
GBP'000 GBP'000
------------------------------------ --------- ---------
Revenue 22,314 16,376
Cost of sales (17,667) (11,245)
-------------------------------------
Gross profit 4,647 5,131
Sales and marketing costs (798) (699)
Other administrative expenses (2,087) (1,860)
Closure of laboratory (226) -
Impairment of intangible assets (50) (414)
Share based payments 20 (112)
------------------------------------- --------- ---------
Administration expenses (2,343) (2,386)
------------------------------------- --------- ---------
Operating profit 1,506 2,046
Finance costs (5) (2)
Finance income 3 -
Contingent consideration no
longer payable on the acquisition
of Nell Health Limited 1,000 -
Impairment of goodwill arising
on acquisition of Nell Health
Limited (987) -
Additional consideration payable
on the
acquisition of The Genome Store
Limited - (40)
------------------------------------- --------- ---------
Profit before income tax 1,517 2,004
Tax charge - -
------------------------------------- --------- ---------
Profit for the year 1,517 2,004
Other comprehensive income - -
------------------------------------- --------- ---------
Total comprehensive profit
for the year 1,517 2,004
------------------------------------- --------- ---------
Attributable to owners of
the parent: 1,517 2,004
Earnings per ordinary share
- basic 0.20p 0.28p
Fully diluted earnings per
ordinary share 0.19p 0.27p
All activities relate to continuing operations.
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
As At 31 December 2022
2022 2021
GBP'000 `GBP'000
------------------------------- --------- ---------
Non-current assets
Property, plant and equipment 75 163
Right of use assets 75 -
Intangible assets 1,098 2,289
Total non-current assets 1,248 2,452
-------------------------------- --------- ---------
Current assets
Inventories 1,284 497
Trade and other receivables 1,288 2,332
Cash and cash equivalents 7,608 6,387
-------------------------------- --------- ---------
Total current assets 10,180 9,216
-------------------------------- --------- ---------
Total assets 11,428 11,668
-------------------------------- --------- ---------
Current liabilities
Trade and other payables 2,525 3,315
Lease liabilities 29 -
Deferred consideration - 1,240
Total current liabilities 2,554 4,555
-------------------------------- --------- ---------
Non-current liabilities
Lease liabilities 24 -
-------------------------------- --------- ---------
Total non-current liabilities 24 -
-------------------------------- --------- ---------
Total liabilities 2,578 4,555
-------------------------------- --------- ---------
Net assets 8,850 7,113
-------------------------------- --------- ---------
Share capital 780 756
Deferred shares 6,359 6,359
Share premium account 16,887 16,671
Capital redemption reserve 1,815 1,815
Reverse acquisition reserve (6,044) (6,044)
Retained earnings (10,947) (12,444)
-------------------------------- --------- ---------
Total equity 8,850 7,113
-------------------------------- --------- ---------
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
Share-based Capital Reverse
Share Deferred Share payment redemption acquisition Retained
capital shares Premium reserve reserve reserve earnings Total
GBP '000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
---------------- --------- ---------- ---------- ------------ ------------- ------------- ----------- --------
Equity as
at
1 January
2021 518 6,359 12,442 916 1,815 (6,044) (15,476) 530
Profit for
the year - - - - - - 2,004 2,004
---------------- --------- ---------- ---------- ------------ ------------- ------------- ----------- --------
Total
comprehensive
profit - - - - - - 2,004 2,004
Transfer from
share based
payment
reserve - - - (916) - - 916 -
Issue of shares
net of
expenses 194 - 2,979 - - - - 3,173
Conversion
of loan note
and interest 13 92 - - - - 105
Exercise of
options 2 - 18 - - - - 20
Other share
issue 1 16 - - - - 17
Share-based
payments - - - - - - 112 112
Acquisition
of Nell Health
Limited 28 1,124 - - - - 1,152
---------------- --------- ---------- ---------- ------------ ------------- ------------- ----------- --------
Equity as
at
31 December
2021 756 6,359 16,671 - 1,815 (6,044) (12,444) 7,113
Profit for
the year - - - - - - 1,517 1,517
---------------- --------- ---------- ---------- ------------ ------------- ------------- ----------- --------
Total
comprehensive
profit - - - - - - 1,517 1,517
Share-based
payments - - - - - - (20) (20)
The Genome
Store Limited
deferred
consideration 24 - 216 - - - - 240
Equity as
at
31 December
2022 780 6,359 16,887 - 1,815 (6,044) (10,947) 8,850
---------------- --------- ---------- ---------- ------------ ------------- ------------- ----------- --------
CONSOLIDATED STATEMENT OF CASH FLOWS
For The Year Ended 31 December 2022
2022 2021
GBP'000 GBP'000
------------------------------------------ -------- --------
Cash flows from operating activities
Profit before taxation 1,517 2,004
Adjustments for:
Deferred consideration (1,000) 40
Decrease in provisions - (26)
Depreciation and amortization 222 157
Impairment of intangible assets 1,365 414
Loss on sale of laboratory assets 55 -
Finance expenses 5 2
Finance income (3) -
Share-based payments (20) 112
Adjusted operating profit before
changes in working capital 2,141 2,703
Changes in working capital
Increase in inventory (787) (494)
Decrease/(Increase) in trade and
other receivables 1,044 (2,124)
(Decrease)/Increase in trade and
other payables (790) 2,931
Cash generated in operations 1,608 3,016
Net interest payable (2) (2)
------------------------------------------ -------- --------
Net cash inflow from operating
activities 1,606 3,014
------------------------------------------ -------- --------
Investing activities
Acquisition of Nell Health Limited - (50)
Purchase of property, plant and
equipment (22) (147)
Purchase of intangible assets (316) (102)
Net cash flows used in investing
activities (338) (299)
------------------------------------------ -------- --------
Financing activities
Issue of ordinary shares (net of
issue expenses) - 3,211
Repayment of lease liability (47) (5)
Net cash flows from financing activities (47) 3,206
------------------------------------------ -------- --------
Net change in cash and cash equivalents 1,221 5,921
Cash and cash equivalents at the
beginning of the year 6,387 466
------------------------------------------ -------- --------
Cash and cash equivalents at the
end of the year 7,608 6,387
------------------------------------------ -------- --------
NOTES TO THE FINANCIAL STATEMENTS
The notes to the Financial Statement are available in full in
the Group Annual Report and Financial Statements which will be
available shortly on the Company website:
www.myhealthcheckedplc.com
Basis of preparation
The financial statements have been prepared in accordance with
UK adopted international accounting standards (IFRS), and with
those parts of the Companies Act 2006 applicable to companies
reporting under IFRS
Earnings per share
2022 2021
Basic and diluted
Profit for the year and earnings used in basic & diluted EPS GBP1,517,000 GBP2,004,000
Weighted average number of shares - basic 774,303,000 710,852,000
Weighted average number of shares - fully diluted 778,223,000 744,056,000
Earnings per share 0.20p 0.28p
Fully diluted earnings per share 0.19p 0.27p
-------------------------------------------------------------- ------------- -------------
Basic earnings per share is calculated by dividing the profit
attributable to equity holders of the Company by the weighted
average number of ordinary shares in issue during the year.
Events after the reporting date
On 17 January 2023 the Court approved the reduction of the share
capital of the Company, involving the cancellation of all the
Deferred Shares, the Share Premium Account and the Capital
Redemption Reserve. The purpose of the Capital Reduction was to
create distributable reserves.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
FR UPUAWCUPWGPG
(END) Dow Jones Newswires
April 03, 2023 02:00 ET (06:00 GMT)
Concepta (LSE:CPT)
Historical Stock Chart
From Oct 2024 to Nov 2024
Concepta (LSE:CPT)
Historical Stock Chart
From Nov 2023 to Nov 2024
